Overview
Compare with OMNICELL, INC., One Stop Systems, Inc. or SOCKET MOBILE, INC., or pick any stock.
- TickerZEPP on NYSE1
- IndustryElectronic Computers1
- HeadquartersGeorge Town, Cayman Islands1
- Incorporated inCayman Islands5
- Business addressBuilding B2, Zhong'An Chuanggu, Technology Park No.900 Wangjiang West Rd, Hefei, 2300885
- Filer categoryNon-accelerated filer5
- Legal formexempt company3
- LEI529900B5C2R4FTJCRN493
- StatusActive3
- LEI statusIssued and current3
- Registered addressc/o MAPLES CORPORATE SERVICES LIMITED, P.O. Box 309, Ugland House, South Church Street, KY1-1104 George Town, Cayman Islands3
- Registered withGeneral Registry, 2947423
See how the biggest companies compare on our leaderboards
We are a global smart wearable and health technology leader. Since our inception in 2013, we have established a strong global presence, particularly in Europe and the U.S. To date, we have shipped over 200 million units of smart wearable devices and served more than 53 million users in over 90 countries with device activation in more than 150 countries.6 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
38.3%Gross margin4
-11.3%Operating margin4
-15.5%Net margin4
41.8%Revenue growth, 20254
-18.7%Return on equity4
0.28×Debt to equity4
-$26.2MFree cash flow4
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
Europe brought in 38% of the revenue Zepp Health broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| Europe | $134.6M | $74.9M | $110.3M |
| Asia Pacific | $181.0M | $75.5M | $91.5M |
| North America | $33.1M | $27.4M | $46.9M |
| United States | $27.2M | $43.6M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue62¢$159.7M
- Research and development18¢$45.3M
- Other costs20¢$51.3M
- Income tax1¢$2.5M
Out of $258.9M in revenue.4 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenues (including US$92,046, US$11,002 and nil with related parties for the years ended December 31, 2023, 2024 and 2025, respectively) | $258.9M | $182.6M | $352.9M |
| Cost of revenues (including US$82,237, US$9,426 and nil resulting from related parties sales for the years ended December 31, 2023, 2024 and 2025, respectively) | $159.7M | $112.4M | $260.5M |
| Gross profit | $99.2M | $70.2M | $92.4M |
| Selling and marketing | $53.8M | $46.5M | $44.5M |
| General and administrative | $29.3M | $24.9M | $26.8M |
| Research and development | $45.3M | $46.2M | $51.5M |
| Total operating expenses | $128.4M | $117.5M | $122.8M |
| Operating loss | -$29.2M | -$47.2M | -$30.4M |
| Interest income | $1.5M | $3.7M | $3.1M |
| Interest expenses | -$5.7M | -$5.6M | -$6.8M |
| Realized gain from investments | $109.0K | ||
| Gain from fair value change of long-term investments | $76.0K | $2.0M | $213.0K |
| Impairment loss from investments | -$2.2M | -$10.1M | -$313.0K |
| Other (expenses)/income, net | $56.0K | -$656.0K | -$525.0K |
| Loss before income tax and loss from equity method investments | -$35.5M | -$57.9M | -$34.6M |
| Income taxes benefits/(expenses) | -$2.5M | -$13.7M | $2.4M |
| Loss before income/(loss) from equity method investments | -$38.0M | -$71.6M | -$32.2M |
| Income/(loss) from equity method investments | -$2.1M | -$4.2M | $1.1M |
| Net loss | -$40.1M | -$75.8M | -$31.1M |
| Less: Net loss attributable to non-controlling interest | -$75.0K | -$66.0K | |
| Net loss attributable to Zepp Health Corporation | -$40.1M | -$75.7M | -$31.0M |
| Net loss attributable to ordinary shareholders of Zepp Health Corporation | -$40.1M | -$75.7M | -$31.0M |
| Basic loss per ordinary share | -$0.16 | -$0.29 | -$0.13 |
| Diluted loss per ordinary share | -$0.16 | -$0.29 | -$0.13 |
| Ordinary share - basic | 254.4M shares | 258.9M shares | 243.1M shares |
| Ordinary share - diluted | 254.4M shares | 258.9M shares | 243.1M shares |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $57.0M | $91.1M | $133.7M | |
| Restricted cash | $55.9M | $19.7M | ||
| Accounts receivable (net of allowance of US$1,457 and US$2,916 as of December 31, 2024 and 2025, respectively) | $66.9M | $63.0M | ||
| Amounts due from related parties (net of allowance of nil and nil as of December 31, 2024 and 2025, respectively) | $6.7M | $2.7M | ||
| Inventories, net | $72.8M | $56.8M | ||
| Short-term investments (including available-for-sale debt securities measured at fair value of US$997 and nil as of December 31, 2024 and 2025, respectively) | $997.0K | |||
| Prepaid expenses and other current assets | $34.3M | $17.4M | ||
| Total current assets | $293.5M | $251.6M | ||
| Property, plant and equipment, net | $5.7M | $6.9M | ||
| Intangible assets, net | $13.6M | $7.1M | ||
| Long-term investments (including available-for-sale debt securities measured at fair value of US$26,666 and US$17,382 as of December 31, 2024 and 2025, respectively) | $220.0M | $225.9M | ||
| Deferred tax assets | $15.7M | $17.5M | ||
| Operating lease right-of-use assets | $2.0M | $3.5M | ||
| Goodwill | $9.6M | $9.6M | ||
| Amounts due from related parties, non-current | $991.0K | $2.0M | ||
| Other non-current assets | $3.7M | $4.6M | ||
| Total assets | $564.8M | $528.6M | ||
| Accounts payable (including accounts payable of the consolidated VIEs without recourse to the Group of US$48,653 and US$64,004 as of December 31, 2024 and 2025, respectively) | $80.8M | $51.1M | ||
| Advance from customers and others of the consolidated VIEs without recourse to the Group | $76.0K | $197.0K | ||
| Income tax payables (including income tax payables of the consolidated VIEs without recourse to the Group of US$69 and US$5 as of December 31, 2024 and 2025, respectively) | $366.0K | $508.0K | ||
| Notes payable and others of the consolidated VIEs without recourse to the Group | $111.7M | $61.7M | ||
| Total current liabilities | $286.8M | $195.4M | ||
| Deferred tax liabilities (including deferred tax liabilities of the consolidated VIEs without recourse to the Group of US$3,015 and US$2,646 as of December 31, 2024 and 2025, respectively) | $2.7M | $3.1M | ||
| Other non-current liabilities of the consolidated VIEs without recourse to the Group | $209.0K | $133.0K | ||
| Non-current operating lease liabilities (including non-current operating lease liabilities of the consolidated VIEs without recourse to the Group of US$308 and nil as of December 31, 2024 and 2025, respectively) | $1.1M | $2.0M | ||
| Total liabilities | $350.3M | $275.9M | ||
| Additional paid-in capital | $280.7M | $278.1M | ||
| Treasury shares | -$16.2M | -$15.0M | ||
| Accumulated retained earnings/(losses) | -$11.4M | $28.6M | ||
| Accumulated other comprehensive loss | -$38.6M | -$40.2M | ||
| Total Zepp Health Corporation shareholders' equity | $214.5M | $251.6M | ||
| Non-controlling interest | $1.1M | |||
| Total equity | $214.5M | $252.7M | $352.8M | $389.3M |
| Total liabilities and equity | $564.8M | $528.6M | ||
| Allowance for doubtful accounts receivable | $2.9M | $1.5M | ||
| Amounts due from related parties, allowance | $0 | $0 | ||
| Short-term investments | $0 | $997.0K | ||
| Long-term investments | $17.4M | $26.7M | ||
| Amounts due to related parties | $654.0K | $2.5M | ||
| Accrued expenses and other current liabilities | $37.5M | $37.6M | ||
| Short-term bank borrowings | $55.7M | $41.9M | ||
| Long-term borrowings | $59.5M | $75.2M | ||
| Ordinary shares, par value | $0.00 | |||
| Ordinary shares, authorized | 405.5M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $57.0M | $91.1M | $133.7M | |
| Restricted cash | $55.9M | $19.7M | ||
| Accounts receivable (net of allowance of US$1,457 and US$2,916 as of December 31, 2024 and 2025, respectively) | $66.9M | $63.0M | ||
| Amounts due from related parties (net of allowance of nil and nil as of December 31, 2024 and 2025, respectively) | $6.7M | $2.7M | ||
| Inventories, net | $72.8M | $56.8M | ||
| Short-term investments (including available-for-sale debt securities measured at fair value of US$997 and nil as of December 31, 2024 and 2025, respectively) | $997.0K | |||
| Prepaid expenses and other current assets | $34.3M | $17.4M | ||
| Total current assets | $293.5M | $251.6M | ||
| Property, plant and equipment, net | $5.7M | $6.9M | ||
| Intangible assets, net | $13.6M | $7.1M | ||
| Long-term investments (including available-for-sale debt securities measured at fair value of US$26,666 and US$17,382 as of December 31, 2024 and 2025, respectively) | $220.0M | $225.9M | ||
| Deferred tax assets | $15.7M | $17.5M | ||
| Operating lease right-of-use assets | $2.0M | $3.5M | ||
| Goodwill | $9.6M | $9.6M | ||
| Amounts due from related parties, non-current | $991.0K | $2.0M | ||
| Other non-current assets | $3.7M | $4.6M | ||
| Total assets | $564.8M | $528.6M | ||
| Accounts payable (including accounts payable of the consolidated VIEs without recourse to the Group of US$48,653 and US$64,004 as of December 31, 2024 and 2025, respectively) | $80.8M | $51.1M | ||
| Advance from customers and others of the consolidated VIEs without recourse to the Group | $76.0K | $197.0K | ||
| Income tax payables (including income tax payables of the consolidated VIEs without recourse to the Group of US$69 and US$5 as of December 31, 2024 and 2025, respectively) | $366.0K | $508.0K | ||
| Notes payable and others of the consolidated VIEs without recourse to the Group | $111.7M | $61.7M | ||
| Total current liabilities | $286.8M | $195.4M | ||
| Deferred tax liabilities (including deferred tax liabilities of the consolidated VIEs without recourse to the Group of US$3,015 and US$2,646 as of December 31, 2024 and 2025, respectively) | $2.7M | $3.1M | ||
| Other non-current liabilities of the consolidated VIEs without recourse to the Group | $209.0K | $133.0K | ||
| Non-current operating lease liabilities (including non-current operating lease liabilities of the consolidated VIEs without recourse to the Group of US$308 and nil as of December 31, 2024 and 2025, respectively) | $1.1M | $2.0M | ||
| Total liabilities | $350.3M | $275.9M | ||
| Additional paid-in capital | $280.7M | $278.1M | ||
| Treasury shares | -$16.2M | -$15.0M | ||
| Accumulated retained earnings/(losses) | -$11.4M | $28.6M | ||
| Accumulated other comprehensive loss | -$38.6M | -$40.2M | ||
| Total Zepp Health Corporation shareholders' equity | $214.5M | $251.6M | ||
| Non-controlling interest | $1.1M | |||
| Total equity | $214.5M | $252.7M | $352.8M | $389.3M |
| Total liabilities and equity | $564.8M | $528.6M | ||
| Allowance for doubtful accounts receivable | $2.9M | $1.5M | ||
| Amounts due from related parties, allowance | $0 | $0 | ||
| Short-term investments | $0 | $997.0K | ||
| Long-term investments | $17.4M | $26.7M | ||
| Amounts due to related parties | $654.0K | $2.5M | ||
| Accrued expenses and other current liabilities | $37.5M | $37.6M | ||
| Short-term bank borrowings | $55.7M | $41.9M | ||
| Long-term borrowings | $59.5M | $75.2M | ||
| Ordinary shares, par value | $0.00 | |||
| Ordinary shares, authorized | 405.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$40.1M | -$75.8M | -$31.1M |
| Non-cash lease expenses | $1.3M | $1.5M | $4.8M |
| Depreciation and amortization | $4.5M | $5.0M | $7.7M |
| Provision for excess and obsolete inventories | $7.8M | $5.2M | $7.3M |
| Share-based compensation | $2.5M | $4.8M | $8.8M |
| (Income)/loss from equity method investments | $2.1M | $4.2M | -$1.1M |
| Loss /(gain) on disposal of property, plant and equipment and others | $21.0K | -$56.0K | $53.0K |
| Gain from fair value change of long-term investments | -$76.0K | -$2.0M | -$213.0K |
| Impairment loss from long-term investments | $1.2M | $8.2M | $313.0K |
| Deferred income taxes | $2.2M | $13.4M | -$2.9M |
| Allowance for doubtful accounts | $7.5M | $1.6M | |
| Impairment loss from short-term investments | $1.0M | $1.9M | |
| Impairment loss from intangible assets | $0 | $0 | $1.1M |
| Realized gain from investments | -$109.0K | ||
| Accounts receivable | -$8.3M | -$5.1M | $36.4M |
| Inventories | -$22.1M | $5.6M | $51.9M |
| Prepaid expenses and other current assets | -$16.2M | -$1.4M | -$745.0K |
| Amounts due from related parties | -$3.2M | $5.5M | $7.4M |
| Other non-current assets | $333.0K | $4.5M | -$2.4M |
| Amounts due to related parties | -$1.9M | -$998.0K | -$2.5M |
| Accounts payable | $28.3M | $14.8M | -$27.8M |
| Notes payable | $11.6M | -$8.6M | -$5.3M |
| Advance from customers | -$126.0K | -$36.0K | -$76.0K |
| Income tax payables | -$189.0K | -$478.0K | $592.0K |
| Accrued expenses and other current liabilities | -$4.0M | -$6.0M | $13.7M |
| Other non-current liabilities | $68.0K | -$129.0K | -$23.3M |
| Net Cash Provided by/(Used in) Operating Activities | -$25.7M | -$24.4M | $42.6M |
| Purchase of property, plant and equipment | -$516.0K | -$1.4M | -$1.6M |
| Disposal of property, plant and equipment | $124.0K | $696.0K | $1.6M |
| Purchase of intangible assets | -$268.0K | -$87.0K | -$83.0K |
| Disposal of intangible assets | $471.0K | $1.1M | $3.1M |
| Loans provided to related parties | -$1.4M | ||
| Disposal of short-term investments | $275.0K | $1.3M | |
| Purchase of long-term investments | -$7.0M | -$282.0K | |
| Disposal of long-term investments | $1.7M | $4.9M | $4.7M |
| Deconsolidation of a subsidiary and others | $427.0K | ||
| Net Cash Provided by/(Used in) by Investing Activities | $1.5M | -$1.6M | $7.7M |
| Bank borrowings received | $65.7M | $11.0M | $56.5M |
| Repayment of bank borrowings | -$73.1M | -$12.6M | -$103.8M |
| Repayment of loan from a related party | $329.0K | ||
| Prepayment for the repurchase of non-controlling interest | -$251.0K | ||
| Repurchase of ordinary shares | -$1.2M | -$2.3M | -$2.5M |
| Letter of credit factoring received | $131.5M | $67.8M | $66.7M |
| Repayment of letter of credit factoring | -$97.0M | -$62.7M | -$58.6M |
| Purchase of non-controlling interest | -$1.1M | -$705.0K | |
| Net Cash (Used in)/Provided by Financing Activities | $24.8M | $477.0K | -$41.7M |
| Net increase /(decrease) in cash and cash equivalents and restricted cash | $623.0K | -$25.5M | $8.7M |
| Effect of exchange rate changes | $1.6M | -$4.2M | -$9.3M |
| Income tax (receipt)/paid- Mainland China | $274.0K | $30.0K | -$116.0K |
| Interest paid | $1.2M | $89.0K | $6.3M |
| Receivable from the disposal of intangible assets | $1.2M | $1.7M | $2.8M |
| Conversion from loan to long-term investment | $2.4M | ||
| Payable/(Receivable) for repurchasing of ordinary shares | -$118.0K | -$100.0K | $59.0K |
| Transfer from other receivables to convertible bonds | $2.0M | ||
| Transfer from convertible bonds to equity investment | $1.1M | ||
| Transfer from convertible bonds to other receivables | $939.0K | ||
| Transfer from equity investment to other non-current assets | $690.0K | ||
| Transfer from long-term investment to intangible assets | $8.5M |
No quarter-by-quarter statement was filed.
Corporate structure
Zepp Health sits at the top of its group. 4 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Zepp Health
- Point72 Asset Management, L.P. Filed SCHEDULE 13G/A on Zepp Health, latest Aug 14, 2026 (3 filings since Jul 18, 2025)
- INTEGRATED CORE STRATEGIES (US) LLC Filed SCHEDULE 13G/A on Zepp Health, latest Aug 13, 2026 (2 filings since Nov 12, 2025)
- Morgan Stanley Filed SCHEDULE 13G/A on Zepp Health, latest Aug 13, 2026 (3 filings since Jun 26, 2026)
- FIL Ltd Filed SCHEDULE 13G/A on Zepp Health, latest Aug 6, 2026 (9 filings since Feb 9, 2022)
- Allspring Global Investments Holdings, LLC Filed SCHEDULE 13G/A on Zepp Health, latest Oct 10, 2025 (9 filings since Dec 9, 2021)
- Shunwei China Internet Fund II, L.P. Filed SC 13G/A on Zepp Health, latest Nov 12, 2024
- GOLDMAN SACHS ASSET MANAGEMENT, L.P. Filed SC 13G/A on Zepp Health, latest Feb 8, 2024
- Wang Huang Filed SC 13G/A on Zepp Health, latest Jan 19, 2024 (4 filings since Jan 28, 2022)
- Franklin Templeton Investments Filed SC 13G/A on Zepp Health, latest Feb 1, 2023 (2 filings since Feb 3, 2022)
- Wells Fargo Filed SC 13G/A on Zepp Health, latest Dec 8, 2021
- Zepp Health George Town, Cayman Islands
- Beijing Shunyuan Kaihua Technology Co Subsidiary
- Huami (Beijing) Information Technology Subsidiary
- Shenzhen Yunding Information Technology Co Subsidiary
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Zepp Health reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Accumulated depreciation | $23.4M4 Dec 31, 2025 | $20.9M4 Dec 31, 2024 | +12.3% |
| Property and equipment, net | $5.7M4 Dec 31, 2025 | $6.9M4 Dec 31, 2024 | −17.9% |
| Operating-lease assets (leased space) | $2.0M4 Dec 31, 2025 | $3.5M4 Dec 31, 2024 | −43.4% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $57.0M4 Dec 31, 2025 | $91.1M4 Dec 31, 2024 | −37.4% |
| Marketable securities, current | $997.0K4 Dec 31, 2024 | $5.2M11 Dec 31, 2023 | −80.7% |
| Long-term investments | $220.0M4 Dec 31, 2025 | $225.9M4 Dec 31, 2024 | −2.6% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $9.6M4 Dec 31, 2025 | $9.6M4 Dec 31, 2024 | 0% |
| Intangible assets, net (excluding goodwill) | $13.6M4 Dec 31, 2025 | $7.1M4 Dec 31, 2024 | +91.9% |
| Accumulated amortization | $15.5M4 Dec 31, 2025 | $12.7M4 Dec 31, 2024 | +22.6% |
| Patents, net | $27.5M4 Dec 31, 2025 | $18.3M4 Dec 31, 2024 | +50.0% |
Inventory
Leadership
Who has led Zepp Health, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
- Chief executive officerWang Huang Mar 16, 2026 to now13
- Chief financial officerCheng Deng Mar 16, 2026 to now14
- Chief operating officerMike Yan Yeung Mar 16, 2026 to now15
Board members and other officers (7)
- Chief Technology OfficerMeihui Fan Mar 16, 2026 to now16
- Chief Industrial DesignerPengtao Yu Mar 16, 2026 to now17
- Board memberHongjiang Zhang Mar 6, 2026 to now18
- Board memberSai Wai Alain Lam Mar 10, 2026 to now19
- Board memberMeihui Fan Mar 16, 2026 to now16
- Board memberMike Yan Yeung Mar 16, 2026 to now15
- Board memberWang Huang Mar 16, 2026 to now13
Subsidiaries and ownership
Subsidiaries
- Beijing Shunyuan Kaihua Technology Co
- Huami (Beijing) Information Technology
- Shenzhen Yunding Information Technology Co
From Wikidata.1
Former names
- Huami CorpNov 6, 2017 to Feb 25, 20215
Timeline
Calendar
Coming up
- Nov 3, 2026Reports results for the quarter ending Sep/202620
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
102 filings to the SEC since October 2021: 7 annual reports, 13 insider forms, 35 large holders, 47 other. The latest 20:
- Sep 25, 20264 OWNERSHIP DOCUMENT EDGAR
- Sep 23, 2026144 EDGAR
- Sep 2, 20266-K EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Aug 12, 2026SCHEDULE 13G/A EDGAR
- Aug 6, 2026SCHEDULE 13G/A EDGAR
- Jun 30, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 29, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 26, 2026144 EDGAR
- Jun 26, 2026SCHEDULE 13G EDGAR
- Jun 9, 20266-K EDGAR
- May 6, 2026SCHEDULE 13G/A EDGAR
- Apr 24, 202620-F EDGAR
- Mar 17, 20263 OWNERSHIP DOCUMENT EDGAR
- Mar 17, 20263 OWNERSHIP DOCUMENT EDGAR
- Mar 16, 20263 OWNERSHIP DOCUMENT EDGAR
- Mar 16, 20263 OWNERSHIP DOCUMENT EDGAR
- Mar 16, 20263 OWNERSHIP DOCUMENT EDGAR
The 102 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
3 open-market trades by officers, directors and large owners since October 2021: 0 buys and 3 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 24, 2026 | Yu PengtaoChief Industrial Designer | Sale | 4,251 | $4.09 | $17.4K | Form 4 |
| Sep 23, 2026 | Yu PengtaoChief Industrial Designer | Sale | 5,749 | $4.30 | $24.7K | Form 4 |
| Jun 26, 2026 | Deng ChengChief Financial Officer | Sale | 9,836 | $4.61 | $45.3K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Point72 Asset Management, L.P.SCHEDULE 13G/A, 3 filings Jul 18, 2025 to Aug 14, 202621
- INTEGRATED CORE STRATEGIES (US) LLCSCHEDULE 13G/A, 2 filings Nov 12, 2025 to Aug 13, 202622
- Morgan StanleySCHEDULE 13G/A, 3 filings Jun 26, 2026 to Aug 13, 202623
- FIL LtdSCHEDULE 13G/A, 9 filings Feb 9, 2022 to Aug 6, 202624
- Allspring Global Investments Holdings, LLCSCHEDULE 13G/A, 9 filings Dec 9, 2021 to Oct 10, 202525
- Shunwei China Internet Fund II, L.P.SC 13G/A, 1 filing Nov 12, 202426
- GOLDMAN SACHS ASSET MANAGEMENT, L.P.SC 13G/A, 1 filing Feb 8, 202427
- Wang HuangSC 13G/A, 4 filings Jan 28, 2022 to Jan 19, 202428
- Franklin Templeton InvestmentsSC 13G/A, 2 filings Feb 3, 2022 to Feb 1, 202329
- Wells FargoSC 13G/A, 1 filing Dec 8, 202130
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Zepp Health is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARZepp Health Corp2
- CIK0001720446
- Filer statusNon-accelerated filer not an emerging growth company; not a shell company6
- Incorporated inCayman Islands6
- Fiscal year endsDecember 312
- Industry code (SIC)3571 Electronic Computers2
- SEC reviewing officeOffice of Technology, Division of Corporation Finance2
- Business addressBuilding B2, Zhong'An Chuanggu, Technology Park No.900 Wangjiang West Rd, Hefei, 230088, China2
- Phone86551-658372002
- Shares outstanding135,608,316 Common Class A shares; 99,277,687 Common Class B shares as of Dec 31, 20256
- AuditorDeloitte Touche Tohmatsu Certified Public Accountants LLP, Beijing, the People’s Republic of China PCAOB ID 1113; no auditor attestation of internal control over financial reporting6
- On EDGAR sinceNov 6, 20172
- Filings197 in all: 6-K (56), SC 13G/A (33), CORRESP (14), SCHEDULE 13G/A (12), SC 13G (11), 3 (10), 20-F (9), UPLOAD (9)2
All 30 form types
144 (5), SCHEDULE 13G (4), 4 (3), DRSLTR (3), EFFECT (3), F-1/A (3), 20-F/A (2), 424B3 (2), 424B4 (2), DRS/A (2), S-8 (2), SC 13D/A (2), 144/A (1), 8-A12B (1), CERT (1), DRS (1), F-1 (1), F-3 (1), F-3/A (1), F-6 (1), F-6 POS (1), SC 13D (1)
- Latest filingsAnnual report (20-F) Apr 24, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| American depositary shares (each representing 16 Class A ordinary shares, par value US$0.0001 per share) | ZEPP | New York Stock Exchange |
| Class A ordinary shares, par value US$0.0001 per share |
From the cover page of the 20-F filed Apr 24, 2026 (Section 12(b) of the Exchange Act).6
Links
- WikidataQ107725159
- SEC EDGARCIK 1720446
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataZepp Health on Wikidata
- 2SEC EDGARZepp Health filings on SEC EDGAR
- 3
- 4SEC EDGARZepp Health 10-K for fiscal 2025
- 5SEC EDGARZepp Health filings on SEC EDGAR
- 6
- 7SEC EDGARZepp Health 10-K for fiscal 2018
- 8SEC EDGARZepp Health 10-K for fiscal 2019
- 9SEC EDGARZepp Health 10-K for fiscal 2020
- 10SEC EDGARZepp Health 10-K for fiscal 2021
- 11SEC EDGARZepp Health 10-K for fiscal 2022
- 12SEC EDGARZepp Health 10-K for fiscal 2022
- 13SEC EDGARWang Huang, Chief executive officer
- 14SEC EDGARCheng Deng, Chief financial officer
- 15
- 16SEC EDGARMeihui Fan, Chief Technology Officer
- 17
- 18SEC EDGARHongjiang Zhang, Board member
- 19SEC EDGARSai Wai Alain Lam, Board member
- 20NasdaqNasdaq calendar
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28SEC EDGARWang Huang SC 13G/A on Zepp Health
- 29
- 30SEC EDGARWells Fargo SC 13G/A on Zepp Health